RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Clinical trials for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat nasopharyngeal cancer
Disease control OngoingThis phase 2 trial is testing whether combining pembrolizumab (an immunotherapy) with olaparib (a PARP inhibitor) can shrink tumors in people with nasopharyngeal cancer that has become resistant to platinum-based chemotherapy. The study plans to enroll 30 adults whose cancer has …
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Two-Antibody combo takes on advanced cancers
Disease control OngoingThis study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise for Hard-to-Treat throat cancer
Disease control OngoingThis study tests a drug called MRG003 in adults whose nasopharyngeal cancer has come back or spread and hasn't responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. About 238 participants will receive the drug, and researchers will…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New cocktail of drugs shows promise for Hard-to-Treat throat cancer
Disease control OngoingThis phase II trial is testing a combination of three drugs—anlotinib, penpulimab, and capecitabine—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study includes 59 adults aged 18 to 65 who have not had prior systemic therapy for their re…
Matched conditions: RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC